Olopatadine Hydrochloride/Mometasone Furoate Monohydrate

2.5亿鼻炎患者迎来治愈新曙光✨ 我国超2.5亿人受过敏性鼻炎困扰，反复鼻塞、喷嚏不断、流涕不止，传统用药只能缓解，停药即复发，62%中重度患者症状难以控制 。如今，国内鼻炎治疗迎来里程碑式突破，多项前沿技术落地，让“摆脱鼻炎”不再是奢望！ 💊 全球首款靶向药落地，精准狙击炎症 2025年，我国自主研发的司普奇拜单抗（康悦达） 获批上市，成为全球首个治疗季节性过敏性鼻炎的IL-4Rα生物制剂 。 - 直接阻断过敏核心通路，从源头抑制喷嚏、鼻塞、流涕等症状 - Ⅲ期临床数据显著，《自然·医学》发文证实：中重度患者症状大幅改善，生活质量明显提升 - 适用于常规药物无效、常年反复发作的难治性患者，告别“用药就好、停药就犯”的循环 🧪 纳米黑科技登场，从根源切断过敏反应 中山大学团队研发有机纳米片“智能吸尘器”技术，登上国际顶级期刊《Advanced Science》 。 - 精准识别并清除引发过敏的“信号兵”（上皮小囊泡），从源头阻止过敏反应发生 - 区别于传统“对症缓解”，实现病因层面干预，为根治鼻炎提供全新方向 🩺 复方鼻喷剂上市，开启鼻炎治疗“复方时代” 国产创新药莱特灵®复方鼻喷剂零发补获批，填补国内空白 。 - 融合多重有效成分，快速缓解鼻塞、流涕、鼻痒等多种症状 - 成人、儿童均可使用，相比单方制剂，疗效更全面，复发率更低 🔬 精准分型+定制治疗，打破“千人一方”困局 武汉大学人民医院率先推行鼻炎精准免疫分型诊疗。 - 通过鼻内镜、血清学检测等多维评估，区分炎症类型 - 结合微创、靶向、免疫治疗，为患者定制专属方案，大幅提升治愈率 告别鼻炎，自由呼吸不再是梦 从传统药物缓解，到如今靶向治疗、纳米技术、精准医疗多线突破，我国鼻炎治疗正式进入“根治探索期”。 这不仅是医学进步，更让2.5亿患者看到希望——不久的将来，彻底摆脱鼻炎困扰，畅快呼吸，自在生活！ 以上内容仅供参考！

NEW YORK--(BUSINESS WIRE)--BlinkRx, the digital pharmacy platform designed to make prescription medications more accessible and affordable, today announced that RYALTRIS® (Olopatadine Hydrochloride and Mometasone Furoate) Nasal Spray, 665 mcg/25 mcg* per spray, is now available for fulfillment through the BlinkRx platform. This follows Glenmark Pharmaceuticals Inc., USA’s transition to direct commercialization and distribution of the product. Patients can now access RYALTRIS® through BlinkRx’s streamlined digital platform as allergy season peaks nationwide. As seasonal allergies reach peak levels in many parts of the country, BlinkRx is helping ensure that patients across the United States can access RYALTRIS® quickly and conveniently. While RYALTRIS® is not available through traditional retail pharmacy channels, patients can benefit from a seamless, end-to-end experience through BlinkRx that includes the best available price and free home delivery. “At BlinkRx, our mission is to ensure that essential medications are easily within reach for everyone. We’re excited to be expanding availability of RYALTRIS® on our platform during the worst seasonal allergies in many parts of the country,” said Geoff Chaiken, co-founder and CEO of BlinkRx. “We are pleased to expand access to RYALTRIS® through BlinkRx, which offers a convenient option for patients,” said Marc Kikuchi, President & Business Head, North America at Glenmark Pharmaceuticals Inc., USA. “As we continue to advance our direct commercialization efforts in the U.S., partnerships like these play a key role in improving how patients access and experience care.” RYALTRIS® is indicated for the treatment of symptoms associated with seasonal allergic rhinitis in adult and pediatric patients 12 years of age and older.1 It is a fixed-dose combination nasal spray that brings together olopatadine hydrochloride (an antihistamine) and mometasone furoate (a corticosteroid) in a single formulation. With demand for allergy relief increasing during the spring season, ensuring reliable and convenient access to effective therapies remains a priority for both providers and patients. Patients interested in finding out if RYALTRIS® is right for them should speak with their healthcare provider to learn more. Patients with existing RYALTRIS® prescriptions can ask their pharmacist to transfer the prescription to BlinkRx. About BlinkRx BlinkRx is redefining the pharmacy experience with integrated data-driven technology that improves patient access to branded medications. Its prescription journey management platform streamlines every step of the process, improving the prescription journey across all stakeholders. Patients enjoy the lowest network price, free home delivery, and personalized support. Healthcare providers benefit from dedicated access teams and enhanced prior authorization support for their patients. Pharmacies are able to access technologies that improve their ability to serve patients. And pharmaceutical manufacturers gain greater transparency from prescription to fulfillment. Learn more at www.blinkrx.com. About Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research‐led, pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com *Calculated on the anhydrous basis 1RYALTRIS® Nasal Spray approved prescribing information, Glenmark Specialty SA, Switzerland. Please click here to view full prescribing information, including Important Safety Information. For additional information about RYALTRIS® and how to access, please visit us.ryaltris.com. RYALTRIS is a registered trademark of Glenmark Specialty SA.